Samsung Bioepis announces Brenzys® (SB4), biosimilar etanercept received approval in South Korea with launch intended late 2015/early 2016.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Sep 07, 2015
Samsung Bioepis announces Brenzys® (SB4), biosimilar etanercept received approval in South Korea with launch intended late 2015/early 2016.
By Bioblast Editor | Sep 03, 2015
Sandoz launches filgrastim biosimilar Zarxio® in US.
By Bioblast Editor | Mar 06, 2015
Sandoz biosimilar Zarxio® approved for US sale with the same indications as Neupogen®, and with a “placeholder” name “figrastim-sndz”. This is the first approval of a biosimilar product in the US.
By Bioblast Editor | Feb 17, 2015
Canadian drug manufacturer Apotex announces FDA has accepted for filing its Biosimilar application for Filgrastim (Grastofil®) along side previous patent Neupogen® within the US Marketplace.
By Bioblast Editor | Jan 05, 2015
FDA accepts Apotex’s s351(k) application for biosimilar Neulasta.
By Bioblast Editor | Sep 18, 2014
US based manufacturer granted approval from EMA to distribute filgrastim biosimilar Accofil®.
By Bioblast Editor | Jan 15, 2014
CA approval for Celltrion/Hospira’s infliximab biosimilar products to be marketed as Remsima® and Inflectra®.
By Bioblast Editor | Oct 17, 2013
EMA welcomes Apotex’s biosimilar Filgrastim rendition, Grastofil®, throughout Europe.
By Bioblast Editor | Sep 10, 2013
Hospira/Celltrion’s infliximab biosimilar products approved in EU (Remsima® and Inflectra®).
By Bioblast Editor | Sep 02, 2011
Stada and Gedeon Richter announce collaboration deals to develop and sell biosimilars rituximab and trastuzumab.
SUBSCRIBE TO PEARCE IP